Citius Oncology, Inc. (NASDAQ:CTOR) Shares Shorted: Short Interest Down 43.1% in September

Citius Oncology, Inc. (NASDAQ:CTOR) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 289,717 shares, a decline of 43.1% from the September 15th total of 509,543 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 129,388 shares, the short-interest ratio is presently 2.2 days.

Institutional Trading of Citius Oncology

An institutional investor recently bought a new stake in Citius Oncology stock. Bank of America Corp DE acquired a new position in shares of Citius Oncology, Inc. (NASDAQ:CTOR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,835,160 shares of the company’s stock, valued at approximately $2,493,000. Bank of America Corp DE owned 4.12% of Citius Oncology at the end of the most recent quarter. 70.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Citius Oncology Stock Performance

Shares of Citius Oncology stock traded up $0.02 during trading on Friday, hitting $0.77. 11,705 shares of the stock were exchanged, compared to its average volume of 100,337. The stock’s fifty day moving average is $0.87 and its 200 day moving average is $0.79. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.34 and a current ratio of 0.73. The stock has a market cap of $71.40 million, a PE ratio of -1.63 and a beta of 3.39. Citius Oncology has a 12 month low of $0.49 and a 12 month high of $1.95.

Citius Oncology (NASDAQ:CTOR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.49 million during the quarter, compared to the consensus estimate of $2.50 million.

About Citius Oncology

Citius Oncology, Inc (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and related serious diseases. The company was established as an oncology-focused subsidiary of Citius Pharmaceuticals and became a separately traded public company following a business combination.

Citius Oncology’s lead product is LYMPHIR (denileukin diftitox-cxdl), a targeted immunotherapy approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.